Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis

por Amanda W. K. AuYeung, Robert C. Mould, Ashley A. Stegelmeier, Jacob P. van Vloten, Khalil Karimi, J. Paul Woods, James J. Petrik, Geoffrey A. Wood, Byram W. Bridle
Publicado 2021

Production and purification of high-titer OrfV for preclinical studies in vaccinology and cancer therapy

por Jacob P. van Vloten, Jessica A. Minott, Thomas M. McAusland, Joelle C. Ingrao, Lisa A. Santry, Grant McFadden, James J. Petrik, Byram W. Bridle, Sarah K. Wootton
Publicado 2021

Enhancing Immune Responses to Cancer Vaccines Using Multi-Site Injections

por Robert C. Mould, Amanda W. K. AuYeung, Jacob P. van Vloten, Leonardo Susta, Anthony J. Mutsaers, James J. Petrik, Geoffrey A. Wood, Sarah K. Wootton, Khalil Karimi, Byram W. Bridle
Publicado 2017

A lung tropic AAV vector improves survival in a mouse model of surfactant B deficiency

por Martin H. Kang, Laura P. van Lieshout, Liqun Xu, Jakob M. Domm, Arul Vadivel, Laurent Renesme, Christian Mühlfeld, Maria Hurskainen, Ivana Mižíková, Yanlong Pei, Jacob P. van Vloten, Sylvia P. Thomas, Claudia Milazzo, Chanèle Cyr-Depauw, Jeffrey A. Whitsett, Lawrence M. Nogee, Sarah K. Wootton, Bernard Thébaud
Publicado 2020